Kim H O, Ji X D, Melman N, Olah M E, Stiles G L, Jacobson K A
Molecular Recognition Section, National Institute of Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
J Med Chem. 1994 Nov 11;37(23):4020-30. doi: 10.1021/jm00049a021.
1,3-Dibutylxanthine 7-riboside has been found to be a partial agonist at A3 adenosine receptors (van Galen et al. Mol. Pharmacol. 1994, 45, 1101-1111). 1,3-Dialkylxanthine 7-riboside analogues modified at the 1-, 3-, and 8-purine positions and at the ribose 5'-position were synthesized. The nucleoside analogues were examined for affinity in radioligand binding assays at rat brain A3 adenosine receptors stably expressed in CHO cells, using the radioligand [[125I]-4-amino-3-iodobenzyl]adenosine-5'-N-methyluronamide (AB-MECA). Affinity was assayed at rat brain A1 and A2a receptors using [3H]PIA and [3H]CGS 21680, respectively. The affinity of xanthine 7-ribosides at A3 receptors depended on the 1,3-dialkyl substituents in the order: Pent > or = Bu >> Hx > Pr approximately Me. 1,3-Dipentylxanthine 7-riboside was slightly selective for A3 receptors (2-fold vs A1 and 10-fold vs A2a). 8-Methoxy substitution was tolerated at A3 receptors. 2-Thio vs 2-oxo substitution increased potency at all three subtypes and slightly increased A3 vs A1 selectivity. The 5'-uronamide modification, which was previously found to enhance A3 selectivity in N6-benzyladenosine derivatives, was also incorporated into the xanthine 7-ribosides, with similar results. The affinity of 1,3-dialkylxanthine 7-riboside 5'-uronamides at A3 receptors depended on the N-alkyluronamide substituent in the order: MeNH > EtNH >> NH2 >> Me2N. Affinity of the 5'-uronamides at A3 receptors was dependent on the 1,3-dialkyl substitution in the order: Bu > Pent > Hex. 1,3-Dibutylxanthine 7-riboside 5'-N-methylcarboxamide, with a Ki value of 229 nM at A3 receptors, was 160-fold selective for rat A3 vs A1 receptors and > 400-fold selective vs A2a receptors. This derivative acted as a full agonist in the A3 receptor-mediated inhibition of adenylate cyclase.
已发现1,3 - 二丁基黄嘌呤7 - 核糖苷是A3腺苷受体的部分激动剂(van Galen等人,《分子药理学》,1994年,45卷,1101 - 1111页)。合成了在嘌呤的1 -、3 - 和8 - 位以及核糖5'-位进行修饰的1,3 - 二烷基黄嘌呤7 - 核糖苷类似物。使用放射性配体[[125I]-4 - 氨基 - 3 - 碘苄基]腺苷 - 5'-N - 甲基脲酰胺(AB - MECA),在稳定表达于CHO细胞的大鼠脑A3腺苷受体的放射性配体结合试验中检测这些核苷类似物的亲和力。分别使用[3H]PIA和[3H]CGS 21680在大鼠脑A1和A2a受体上测定亲和力。黄嘌呤7 - 核糖苷在A3受体上的亲和力取决于1,3 - 二烷基取代基,顺序为:戊基≥丁基>>己基>丙基≈甲基。1,3 - 二戊基黄嘌呤7 - 核糖苷对A3受体有轻微选择性(对A1受体为2倍,对A2a受体为10倍)。A3受体可耐受8 - 甲氧基取代。2 - 硫代取代相对于2 - 氧代取代增加了所有三种亚型的效力,并略微增加了A3相对于A1的选择性。先前发现可增强N6 - 苄基腺苷衍生物中A3选择性的5'-脲酰胺修饰也被引入黄嘌呤7 - 核糖苷中,结果相似。1,3 - 二烷基黄嘌呤7 - 核糖苷5'-脲酰胺在A3受体上的亲和力取决于N - 烷基脲酰胺取代基,顺序为:甲氨基>乙氨基>>氨基>>二甲氨基。5'-脲酰胺在A3受体上的亲和力取决于1,3 - 二烷基取代,顺序为:丁基>戊基>己基。1,3 - 二丁基黄嘌呤7 - 核糖苷5'-N - 甲基甲酰胺在A3受体上的Ki值为229 nM,对大鼠A3受体相对于A1受体的选择性为160倍,相对于A2a受体的选择性>400倍。该衍生物在A3受体介导的腺苷酸环化酶抑制中起完全激动剂的作用。